FDA Staff Recommends Rejection of Novartis Heart-Failure Drug Wall Street Journal The FDA's medical review said the data didn't show serelaxin slowed progress of heart failure nor did it "provide persuasive evidence of an effect" on shortness of breath, a main heart-failure symptom. The unusually negative review from FDA staff doesn ... |
